Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric

Status Completed

Clinical Trial Summary

- Introduction: Estrogen hormonal therapy associated or not with progestagen is the standard therapy for the treatment of hot flushes. However some women are not candidates for hormone replacement therapy for medical reasons or for choice.

- Main goal: Reducing the number of hot flushes per week

- Materials and Methods: A double-blind sulpiride versus placebo that includes selected randomized patients which show symptoms of menopause. The study will be conducted at HC Porto Alegre (Brazil) for 8 weeks of intervention. The expected result is a significant reduction in the number of hot flushes/day evaluated by daily questionnaires

Clinical Trial Description

It will be held 4 visits. The V0 (first one) to implement the consent form, review the inclusion and exclusion criteria and laboratory exams and deliver the diary book of hot flushes. The V1 (second visit) randomization and provide medication for the first 30 days. The V2 (third visit) to make the record diary of hot flushes already filled, to deliver new specifications and to provide medication for the last 30 days. The V3 (fourth visit) to evaluate the record diary of hot flushes already completed and to make a final evaluation of the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02749747
Study type	Interventional
Source	Hospital de Clinicas de Porto Alegre
Contact
Status	Completed
Phase	Phase 3
Start date	June 2014
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04587154` - Womens Study to Alleviate Vasomotor Symptoms	N/A
Terminated	`NCT03642119` - Validation of an Objective Instrument to Measure Hot Flashes During Menopause
Completed	`NCT05061563` - A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults	Phase 1
Completed	`NCT05419908` - Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes	Phase 2
Completed	`NCT01281332` - Mechanical Device for the Relief of Hot Flashes	Phase 2
Completed	`NCT01439945` - Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer	Phase 2
Completed	`NCT00755417` - Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women	Phase 3
Completed	`NCT01293695` - Hypnosis For Hot Flashes Among Postmenopausal Women in a Randomized Clinical Trial	N/A
Completed	`NCT00599456` - Investigation of the Usefulness of Omega 3 Vitamins in the Relief of Hot Flashes in Menopausal Women.	N/A
Completed	`NCT00256685` - Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause	Phase 3
Completed	`NCT00391417` - Efficacy and Safety of a Topical Estradiol Gel for Treatment of Postmenopausal Symptoms	Phase 3
Terminated	`NCT00244894` - Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer	N/A
Completed	`NCT00010712` - Effects of Black Cohosh on Menopausal Hot Flashes	Phase 2
Active, not recruiting	`NCT03580499` - Vitamin B6 in Reducing Hot Flashes in Participants With Prostate Cancer Undergoing Antiandrogen Therapy	N/A
Recruiting	`NCT06030388` - Strength and Aerobic Training Against Hot Flushes in Postmenopausal Women	N/A
Recruiting	`NCT04418115` - Fatigue as a Late Effect in Breast Cancer Survivors - is Acupuncture a Treatment Option?	N/A
Recruiting	`NCT04861701` - Effect and Predictors for Hot Flush in Women Undergoing Static Stretching Exercise	N/A
Active, not recruiting	`NCT05086705` - EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer	N/A
Completed	`NCT05099159` - A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)	Phase 3
Completed	`NCT01140646` - Evaluation of SAMe for Hot Flashes	Phase 2